Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas

mBio

Volumn 6, Issue 2, 2015, Pages 1-22

  Barbian, Hannah J ^a   Decker, Julie M ^b   Bibollet Ruche, Frederic ^a   Galimidi, Rachel P ^c   West, Anthony P ^c   Learn, Gerald H ^a   Parrish, Nicholas F ^a   Iyer, Shilpa S ^a   Li, Yingying ^a   Pace, Craig S ^d   Song, Ruijiang ^e   Huang, Yaoxing ^e   Denny, Thomas N ^f   Mouquet, Hugo ^e,g   Martin, Loic ^h   Acharya, Priyamvada ⁱ   Zhang, Baoshan ⁱ   Kwong, Peter D ⁱ   Mascola, John R ⁱ   Theo Verrips, C ^j   Strokappe, Nika M ^k   Rutten, Lucy ^k   McCoy, Laura E ^l   Weiss, Robin A ^l   Brown, Corrine S ^m   Jackson, Raven ^m   Silvestri, Guido ⁿ   Connors, Mark ⁱ   Burton, Dennis R ^o   Shaw, George M ^a   Nussenzweig, Michel C ^e   Bjorkman, Pamela J ^c   Ho, David D ^e   Farzan, Michael ^p   Hahn, Beatrice H ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Alabama at Birmingham   (United States)

^c California Institute of Technology   (United States)

^d GILEAD SCIENCES   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INSTITUT PASTEUR   (France)

^h SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j QVQ BV   (Netherlands)

^k UTRECHT UNIVERSITY   (Netherlands)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m Chimp Haven Inc   (United States)

ⁿ EMORY UNIVERSITY   (United States)

^o SCRIPPS RESEARCH INSTITUTE   (United States)

^p SCRIPPS RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD4 IMMUNOGLOBULIN; CHEMOKINE RECEPTOR CCR5; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; PEPTIDOGLYCAN; PRO 140; VIRUS GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CHIMPANZEE; FEMALE; GORILLA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; NONHUMAN; PAN TROGLODYTES; PAN TROGLODYTES SCHWEINFURTHII; PAN TROGLODYTES TROGLODYTES; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; CROSS REACTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; SERODIAGNOSIS; VIROLOGY;

GORILLA GORILLA GORILLA; HUMAN IMMUNODEFICIENCY VIRUS 1; LAMA (MAMMAL); PAN; PAN TROGLODYTES SCHWEINFURTHII; PAN TROGLODYTES TROGLODYTES; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; GORILLA GORILLA; HIV ANTIBODIES; HUMANS; INHIBITORY CONCENTRATION 50; NEUTRALIZATION TESTS; PAN TROGLODYTES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84928796289     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00296-15     Document Type: Article

References (137)

1. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1:a006841. http://dx.doi.org/10.1101/cshperspect.a006841.
2. Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH, Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S, Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp PM, Shaw GM, Pusey AE, Hahn BH. 2009. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 460:515–519. http://dx.doi.org/10.1038/nature08200.
3. Rudicell RS, Holland Jones J, Wroblewski EE, Learn GH, Li Y, Robertson JD, Greengrass E, Grossmann F, Kamenya S, Pintea L, Mjungu DC, Lonsdorf EV, Mosser A, Lehman C, Collins DA, Keele BF, Goodall J, Hahn BH, Pusey AE, Wilson ML. 2010. Impact of simian immunodeficiency virus infection on chimpanzee population dynamics. PLoS Pathog 6:e1001116. http://dx.doi.org/10.1371/journal.ppat.1001116.
4. Terio KA, Kinsel MJ, Raphael J, Mlengeya T, Lipende I, Kirchhoff CA, Gilagiza B, Wilson ML, Kamenya S, Estes JD. 2011. Pathologic lesions in chimpanzees (Pan trogylodytes schweinfurthii) from Gombe National Parks, Tanzania: 2004 –2010. J Zoo Wildl Med 42:597– 607. http:// dx.doi.org/10.1638/2010-0237.1.
5. Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, Marx PA, Hahn BH, Sharp PM. 2003. Hybrid origin of SIV in chimpanzees. Science 300:1713. http://dx.doi.org/10.1126/science.1080657.
6. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523–526. http://dx.doi.org/10.1126/science.1126531.
7. Li Y, Ndjango J-B, Learn GH, Ramirez MA, Keele BF, Bibollet-Ruche F, Liu W, Easlick JL, Decker JM, Rudicell RS, Inogwabini B-I, Ahuka- Mundeke S, Leendertz FH, Reynolds V, Muller MN, Chancellor RL, Rundus AS, Simmons N, Worobey M, Shaw GM, Peeters M, Sharp PM, Hahn BH. 2012. Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir. J Virol 86:10776–10791. http://dx.doi.org/10.1128/JVI.01498-12.
8. Santiago ML, Rodenburg CM, Kamenya S, Bibollet-Ruche F, Gao F, Bailes E, Meleth S, Soong S-J, Kilby JM, Moldoveanu Z, Fahey B, Muller MN, Ayouba A, Nerrienet E, McClure HM, Heeney JL, Pusey AE, Collins DA, Boesch C, Wrangham RW, Goodall J, Sharp PM, Shaw GM, Hahn BH. 2002. SIVcpz in wild chimpanzees. Science 295: 465. http://dx.doi.org/10.1126/science.295.5554.465.
9. Santiago ML, Lukasik M, Kamenya S, Li Y, Bibollet-Ruche F, Bailes E, Muller MN, Emery M, Goldenberg DA, Lwanga JS, Ayouba A, Nerrienet E, McClure HM, Heeney JL, Watts DP, Pusey AE, Collins DA, Wrangham RW, Goodall J, Brookfield JFY, Sharp PM, Shaw GM, Hahn BH. 2003. Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees (Pan troglodytes schweinfurthii). J Virol 77:7545–7562. http://dx.doi.org/10.1128/JVI.77.13.7545-7562.2003.
10. Rudicell RS, Piel AK, Stewart F, Moore DL, Learn GH, Li Y, Takehisa J, Pintea L, Shaw GM, Moore J, Sharp PM, Hahn BH. 2011. High prevalence of simian immunodeficiency virus infection in a community of savanna chimpanzees. J Virol 85:9918 –9928. http://dx.doi.org/ 10.1128/JVI.05475-11.
11. Van Heuverswyn F, Li Y, Bailes E, Neel C, Lafay B, Keele BF, Shaw KS, Takehisa J, Kraus MH, Loul S, Butel C, Liegeois F, Yangda B, Sharp PM, Mpoudi-Ngole E, Delaporte E, Hahn BH, Peeters M. 2007. Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology 368:155–171. http://dx.doi.org/10.1016/j.virol.2007.06.018.
12. Piel AK, Stewart FA, Pintea L, Li Y, Ramirez MA, Loy DE, Crystal PA, Learn GH, Knapp LA, Sharp PM, Hahn BH. 2013. The Malagarasi River does not form an absolute barrier to chimpanzee movement in western Tanzania. PLoS One 8:e58965. http://dx.doi.org/10.1371/journal.pone.0058965.
13. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, Loul S, Butel C, Liegeois F, Bienvenue Y, Ngolle EM, Sharp PM, Shaw GM, Delaporte E, Hahn BH, Peeters M. 2006. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 444:164. http://dx.doi.org/10.1038/444164a.
14. Etienne L, Locatelli S, Ayouba A, Esteban A, Butel C, Liegeois F, Aghokeng A, Delaporte E, Mpoudi Ngole E, Peeters M. 2012. Noninvasive follow-up of simian immunodeficiency virus infection in wildliving nonhabituated western lowland gorillas in Cameroon. J Virol 86: 9760–9772. http://dx.doi.org/10.1128/JVI.01186-12.
15. Takehisa J, Kraus MH, Ayouba A, Bailes E, Van Heuverswyn F, Decker JM, Li Y, Rudicell RS, Learn GH, Neel C, Ngole EM, Shaw GM, Peeters M, Sharp PM, Hahn BH. 2009. Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J Virol 83: 1635–1648. http://dx.doi.org/10.1128/JVI.02311-08.
16. D’Arc M, Ayouba A, Esteban A, Learn GH, Boué V, Liegeois F, Etienne L, Tagg N, Leendertz FH, Boesch C, Madinda NF, Robbins MM, Gray M, Cournil A, Ooms M, Letko M, Simon VA, Sharp PM, Hahn BH, Delaporte E, Ngole EM, Peeters M. 2015. Origin of the HIV-1 group O epidemic in western lowland gorillas. Proc Natl Acad Sci U S A http://dx.doi.org/10.1073/pnas.1502022112.
17. Walsh PD, Abernethy KA, Bermejo M, Beyers R, De Wachter P, Akou ME, Huijbregts B, Mambounga DI, Toham AK, Kilbourn AM, Lahm SA, Latour S, Maisels F, Mbina C, Mihindou Y, Obiang SN, Effa EN, Starkey MP, Telfer P, Thibault M, Tutin CEG, White LJT, Wilkie DS. 2003. Catastrophic ape decline in western equatorial Africa. Nature 422: 611–614. http://dx.doi.org/10.1038/nature01566.
18. Weiss RA, Heeney JL. 2009. Infectious diseases: an ill wind for wild chimps? Nature 460:470–471. http://dx.doi.org/10.1038/460470a.
19. Ryan SJ, Walsh PD. 2011. Consequences of non-intervention for infectious disease in African great apes. PLoS One 6:e29030. http://dx.doi.org/ 10.1371/journal.pone.0029030.
20. Heeney JL, Rutjens E, Verschoor EJ, Niphuis H, ten Haaft P, Rouse S, McClure H, Balla-Jhagjhoorsingh S, Bogers W, Salas M, Cobb K, Kestens L, Davis D, van der Groen G, Courgnaud V, Peeters M, Murthy KK. 2006. Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficiency virus type 1 infection in chimpanzees. J Virol 80:7208–7218. http://dx.doi.org/10.1128/JVI.00382-06.
21. Fultz PN, McClure HM, Swenson RB, McGrath CR, Brodie A, Getchell JP, Jensen FC, Anderson DC, Broderson JR, Francis DP. 1986. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol 58:116–124.
22. Novembre FJ, de Rosayro J, Nidtha S, O’Neil SP, Gibson TR, Evans- Strickfaden T, Hart CE, McClure HM. 2001. Rapid CD4 T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees. J Virol 75:1533–1539. http://dx.doi.org/10.1128/JVI.75.3.1533-1539.2001.
23. Hu SL, Fultz PN, McClure HM, Eichberg JW, Thomas EK, Zarling J, Singhal MC, Kosowski SG, Swenson RB, Anderson DC, Todaro G. 1987. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature 328:721–723. http://dx.doi.org/10.1038/328721a0.
24. Altevogt BM, Pankevich DE, Shelton-Davenport MK, Kahn JP (ed). 2011. Chimpanzees in biomedical and behavioral research: assessing the necessity. Institute of Medicine (US) and National Research Council (US) Committee on the Use of Chimpanzees in Biomedical and Behavioral Research. National Academies Press, Washington, DC.
25. Warfield KL, Goetzmann JE, Biggins JE, Kasda MB, Unfer RC, Vu H, Aman MJ, Olinger GG, Walsh PD. 2014. Vaccinating captive chimpanzees to save wild chimpanzees. Proc Natl Acad Sci U S A 111:8873–8876. http://dx.doi.org/10.1073/pnas.1316902111.
26. Weiss RA. 2014. Immunotherapy for HIV infection. N Engl J Med 370: 379–380. http://dx.doi.org/10.1056/NEJMcibr1314577.
27. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Protocol G, Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289. http://dx.doi.org/10.1126/science.1178746.
28. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang SK, Ramos A, Chan-Hui P-Y, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong C-H, Phogat S, Wrin T, Simek MD, Protocol G, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466 – 470. http:// dx.doi.org/10.1038/nature10373.
29. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O’Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856–861. http://dx.doi.org/10.1126/science.1187659.
30. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81– 84. http://dx.doi.org/10.1038/nature10660.
31. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. 2009. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15:901–906. http://dx.doi.org/10.1038/nm.1967.
32. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. 2009. Effective, lowtiter antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951–954. http://dx.doi.org/10.1038/ nm.1974.
33. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–210. http://dx.doi.org/10.1038/72318.
34. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433. http://dx.doi.org/10.1371/journal.ppat.1000433.
35. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu R-B, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492: 118–122. http://dx.doi.org/10.1038/nature11604.
36. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA. 2013. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277–280. http://dx.doi.org/10.1038/nature12746.
37. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang H-W, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys. Nature 503:224 –228. http://dx.doi.org/10.1038/nature12744.
38. Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, An DS, Baltimore D. 2014. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20:296 –300. http:// dx.doi.org/10.1038/nm.3471.
39. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369: 2097–2105. http://dx.doi.org/10.1016/S0140-6736(07)60982-9.
40. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Pang J-J, Roman AJ, Byrne BJ, Jacobson SG. 2009. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20:999 –1004. http://dx.doi.org/10.1089/hum.2009.086.
41. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O’Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365:2357–2365. http://dx.doi.org/10.1056/NEJMoa1108046.
42. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma J-X, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. 2008. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358:2240–2248. http://dx.doi.org/ 10.1056/NEJMoa0802315.
43. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. 2002. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 76:8769–8775. http://dx.doi.org/10.1128/JVI.76.17.8769-8775.2002.
44. Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M. 2007. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 81: 11016–11031. http://dx.doi.org/10.1128/JVI.01340-07.
45. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11:615– 622. http://dx.doi.org/10.1038/nm1244.
46. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412–425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
47. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. 2013. Antibodies in HIV-1 vaccine development and therapy. Science 341:1199–1204. http://dx.doi.org/10.1126/science.1241144.
48. Burton DR, Poignard P, Stanfield RL, Wilson IA. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337:183–186. http://dx.doi.org/10.1126/science.1225416.
49. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406–412. http://dx.doi.org/10.1038/nature11544.
50. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892–10905. http://dx.doi.org/10.1128/JVI.75.22.10892-10905.2001.
51. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O’Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang Z-Y, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593–1602. http://dx.doi.org/10.1126/science.1207532.
52. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper- Stromberg A, Gnanapragasam PN, Spencer DI, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109:E3268–E3277. http://dx.doi.org/10.1073/pnas.1217207109.
53. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Georgiev IS, Chuang G-Y, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. 2014. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:138–142. http://dx.doi.org/10.1038/nature13601.
54. Scharf L, Scheid JF, Lee JH, West AP, Jr, Chen C, Gao H, Gnanapragasam PN, Mares R, Seaman MS, Ward AB, Nussenzweig MC, Bjorkman PJ. 2014. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7:785–795. http://dx.doi.org/10.1016/j.celrep.2014.04.001.
55. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Peña AT, Cupo A, Julien J-P, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. 2014. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40: 669–680. http://dx.doi.org/10.1016/j.immuni.2014.04.008.
56. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang C-H, McBride R, von Bredow B, Shivatare SS, Wu C-Y, Chan-Hui P-Y, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong C-H, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR. 2014. Broadly neutralizing HIV antibodies define a glycandependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40:657– 668. http://dx.doi.org/10.1016/ j.immuni.2014.04.009.
57. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC. 2001. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 75:579–588. http://dx.doi.org/10.1128/ JVI.75.2.579-588.2001.
58. Dimitrov A. 2007. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr Opin Investig Drugs 8:653–661.
59. Song R, Oren DA, Franco D, Seaman MS, Ho DD. 2013. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat Biotechnol 31:1047–1052. http:// dx.doi.org/10.1038/nbt.2677.
60. Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD. 2013. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A 110:13540 –13545. http://dx.doi.org/10.1073/pnas.1304985110.
61. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, Broder S, Smith, DH. 1989. Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525–531. http://dx.doi.org/10.1038/337525a0.
62. West AP, Jr, Galimidi RP, Foglesong CP, Gnanapragasam PN, Klein JS, Bjorkman PJ. 2010. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J Virol 84:261–269. http://dx.doi.org/10.1128/JVI.01528-09.
63. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. 2015. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:87–91. http://dx.doi.org/10.1038/ nature14264.
64. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439–1452. http://dx.doi.org/10.1128/JVI.02108-09.
65. Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, Greene KM, McCutchan F, Williamson C, Kim JH, Tovanabutra S, Hahn BH, Swanstrom R, Thomson MM, Gao F, Harris L, Giorgi E, Hengartner N, Bhattacharya T, Mascola JR, Montefiori DC. 2014. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol 88:12623–12643. http://dx.doi.org/ 10.1128/JVI.01705-14.
66. Novembre FJ, Saucier M, Anderson DC, Klumpp SA, O’Neil SP, Brown CR, Hart CE, Guenthner PC, Swenson RB, McClure HM. 1997. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol 71:4086–4091.
67. Peeters M, Fransen K, Delaporte E, van den Haesevelde M, Gershy- Damet GM, Kestens L, van der Groen G, Piot P. 1992. Isolation and characterization of a new chimpanzee lentivirus (simian immunodeficiency virus isolate cpz-ant) from a wild-captured chimpanzee. AIDS 6:447–451. http://dx.doi.org/10.1097/00002030-199205000-00002.
68. Huet T, Cheynier R, Meyerhans A, Roelants G, Wain-Hobson S. 1990. Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 345:356–359. http://dx.doi.org/10.1038/345356a0.
69. Bibollet-Ruche F, Gao F, Bailes E, Saragosti S, Delaporte E, Peeters M, Shaw GM, Hahn BH, Sharp PM. 2004. Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2). AIDS Res Hum Retroviruses 20:1377–1381. http://dx.doi.org/10.1089/ aid.2004.20.1377.
70. Takehisa J, Kraus MH, Decker JM, Li Y, Keele BF, Bibollet-Ruche F, Zammit KP, Weng Z, Santiago ML, Kamenya S, Wilson ML, Pusey AE, Bailes E, Sharp PM, Shaw GM, Hahn BH. 2007. Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees. J Virol 81:7463–7475. http://dx.doi.org/10.1128/JVI.00551-07.
71. Bibollet-Ruche F, Heigele A, Keele BF, Easlick JL, Decker JM, Takehisa J, Learn G, Sharp PM, Hahn BH, Kirchhoff F. 2012. Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation. J Clin Invest 122:1644 –1652. http://dx.doi.org/10.1172/ JCI61429.
72. Hvilsom C, Carlsen F, Siegismund HR, Corbet S, Nerrienet E, Fomsgaard A. 2008. Genetic subspecies diversity of the chimpanzee CD4 virus-receptor gene. Genomics 92:322–328. http://dx.doi.org/10.1016/j.ygeno.2008.07.003.
73. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. 1991. An IgG human monoclonal antibody that reacts with HIV-1/ GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 146:4325–4332.
74. Barbas CF, III, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR, Haigwood NL, Cabezas E, Satterthwait AC, Sanz I, Burton DR. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 230:812– 823. http://dx.doi.org/10.1006/jmbi.1993.1203.
75. Diskin R, Scheid JF, Marcovecchio PM, West AP, Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289 –1293. http://dx.doi.org/10.1126/science.1213782.
76. McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman MS, Mortier D, Rutten L, Chander N, Edwards CJ, Ketteler R, Davis D, Verrips T, Weiss RA. 2012. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med 209:1091–1103. http://dx.doi.org/10.1084/jem.20112655.
77. Chen L, Kwon YD, Zhou T, Wu X, O’Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang Z-Y, Zhang M-Y, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123–1127. http://dx.doi.org/10.1126/science.1175868.
78. Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC 01. Science 329:811–817. http://dx.doi.org/10.1126/science.1192819.
79. Li Y, O’Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC 01. J Virol 85:8954–8967. http://dx.doi.org/10.1128/JVI.00754-11.
80. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF, Burton DR, Ho DD, Moore JP. 1995. Crossclade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69:6609–6617.
81. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1¡2 mannose residues on the outer face of gp120. J Virol 76:7306–7321. http://dx.doi.org/10.1128/JVI.76.14.7306-7321.2002.
82. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien J-P, Menis S, Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR. 2014. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6:236ra63. http://dx.doi.org/10.1126/scitranslmed.3008104.
83. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O’Dell S, Patel N, Shahzad-ul- Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang Z-Y, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang L-X, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336–343.
84. Doria-Rose NA, Georgiev I, O’Dell S, Chuang G-Y, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, Burton DR, Koff WC, Kwong PD, Mascola JR. 2012. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 86:8319–8323. http://dx.doi.org/10.1128/JVI.00696-12.
85. Sagar M, Wu X, Lee S, Overbaugh J. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80:9586 –9598. http:// dx.doi.org/10.1128/JVI.00141-06.
86. Van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw- Klein M, Verwer N, Schuitemaker H. 2011. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J Virol 85:6986–6995. http://dx.doi.org/10.1128/JVI.00268-11.
87. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Verrips T, De Haard H, Weiss RA. 2008. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 82:12069 –12081. http://dx.doi.org/10.1128/JVI.01379-08.
88. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Forsman Quigley A, Hulsik DL, Chen L, Weiss R, De Haard H, Verrips T. 2012. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS One 7:e33298. http://dx.doi.org/10.1371/journal.pone.0033298.
89. Acharya P, Luongo TS, Georgiev IS, Matz J, Schmidt SD, Louder MK, Kessler P, Yang Y, McKee K, O’Dell S, Chen L, Baty D, Chames P, Martin L, Mascola JR, Kwong PD. 2013. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4- induced epitope that includes elements of coreceptor- and CD4-binding sites. J Virol 87:10173–10181. http://dx.doi.org/10.1128/JVI.01332-13.
90. Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F, Baty D, Martin L, Benichou S, Chames P. 2013. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol 87:1137–1149. http://dx.doi.org/10.1128/JVI.00461-12.
91. McCoy LE, Rutten L, Frampton D, Anderson I, Granger L, Bashford- Rogers R, Dekkers G, Strokappe NM, Seaman MS, Koh W, Grippo V, Kliche A, Verrips T, Kellam P, Fassati A, Weiss RA. 2014. Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog 10:e1004552. http://dx.doi.org/10.1371/journal.ppat.1004552.
92. Strokappe NM. 2013. HIV-1, how llamas help us fight the AIDS pandemic. Ph.D. thesis. Utrecht University Repository, Utrecht, the Netherlands.
93. Lutje Hulsik D, Liu Y-Y, Strokappe NM, Battella S, El-Khattabi M, McCoy LE, Sabin C, Hinz A, Hock M, Macheboeuf P, Bonvin AM, Langedijk JP, Davis D, Forsman Quigley A, Aasa-Chapman MM, Seaman MS, Ramos A, Poignard P, Favier A, Simorre JP. 2013. A gp41 MPER-specific llamaVHHrequires a hydrophobic CDR3 for neutralization but not for antigen recognition. PLoS Pathog 9:e1003202. http://dx.doi.org/10.1371/journal.ppat.1003202.
94. Zacharova V, Zachar V, Goustin AS. 1997. Sequence of chemokine receptor gene CCR5 in chimpanzees, a natural HIV type 1 host. AIDS Res Hum Retroviruses 13:1159 –1161. http://dx.doi.org/10.1089/aid.1997.13.1159.
95. Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D’Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC. 2008. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 198: 1345–1352. http://dx.doi.org/10.1086/592169.
96. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST. 2009. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 53:450–457. http://dx.doi.org/10.1128/AAC.00942-08.
97. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, Shanahan WR. 2004. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX- 355 in patients infected with HIV type 1. J Infect Dis 189:286–291. http:// dx.doi.org/10.1086/380802.
98. Bruno CJ, Jacobson JM. 2010. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother 65:1839–1841. http://dx.doi.org/10.1093/jac/dkq261.
99. Song R, Franco D, Kao C-Y, Yu F, Huang Y, Ho DD. 2010. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol 84:6935– 6942. http://dx.doi.org/10.1128/JVI.00453-10.
100. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin MC, Koup RA, McDougal JS, Maddon PJ. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11:533–539. http://dx.doi.org/10.1089/aid.1995.11.533.
101. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ. 1987. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 238:1704 –1707. http://dx.doi.org/10.1126/ science.3500514.
102. Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA, Johnson JS, Cossum P, Chamow SM, Wurm FM, Gregory T, Groopman JE, Capon DJ. 1990. Biological properties of a CD4 immunoadhesin. Nature 344: 667–670. http://dx.doi.org/10.1038/344667a0.
103. Choe H, Li W, Wright PL, Vasilieva N, Venturi M, Huang C-C, Grundner C, Dorfman T, Zwick MB, Wang L, Rosenberg ES, Kwong PD, Burton DR, Robinson JE, Sodroski JG, Farzan M. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114:161–170. http://dx.doi.org/10.1016/S0092-8674(03)00508-7.
104. Dorfman T, Moore MJ, Guth AC, Choe H, Farzan M. 2006. A tyrosinesulfated peptide derived from the heavy-chain CDR3 region of an HIV- 1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem 281:28529–28535. http://dx.doi.org/10.1074/jbc.M602732200.
105. Kwong JA, Dorfman T, Quinlan BD, Chiang JJ, Ahmed AA, Choe H, Farzan M. 2011. A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein. J Virol 85:7563–7571. http://dx.doi.org/10.1128/JVI.00630-11.
106. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302–1307. http://dx.doi.org/10.1038/3293.
107. Liao H-X, Lynch R, Zhou T, Gao F, MunirAlam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, NISC Comparative Sequencing Program, Mullikin JC, Gnanakaran, S, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BTM, Kwong PD, Haynes BF. 2013. Coevolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496:469–476.
108. Mouquet H, Nussenzweig MC. 2013. HIV: roadmaps to a vaccine. Nature 496:441–442. http://dx.doi.org/10.1038/nature12091.
109. Gao F, Bonsignori M, Liao H-X, Kumar A, Xia S-M, Lu X, Cai F, Hwang K-K, Song H, Zhou T, Lynch RM, Alam SM, Moody MA, Ferrari G, Berrong M, Kelsoe G, Shaw GM, Hahn BH, Montefiori DC, Kamanga G, Cohen MS, Hraber P, Kwong PD, Korber BT, Mascola JR, Kepler TB, Haynes BF. 2014. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158:481–491. http://dx.doi.org/10.1016/j.cell.2014.06.022.
110. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648–659. http://dx.doi.org/10.1038/31405.
111. Georgiev IS, Doria-Rose NA, Zhou T, Do Kwon YD, Staupe RP, Moquin S, Chuang G-Y, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O’Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA. 2013. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340:751–756. http://dx.doi.org/10.1126/science.1233989.
112. Pace CS, Fordyce MW, Franco D, Kao C-Y, Seaman MS, Ho DD. 2013. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr 62:1–9. http:// dx.doi.org/10.1097/QAI.0b013e3182732746.
113. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, Chisholm P. 1992. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 149: 1779 –1787.
114. Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T. 1999. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 73:4145–4155.
115. Pegu A, Yang Z-Y, Boyington JC, Wu L, Ko S-Y, Schmidt SD, McKee K, Kong W-P, Shi W, Chen X, Todd J-P, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. 2014. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6:243ra88. http://dx.doi.org/10.1126/scitranslmed.3008992.
116. Poignard P, Moldt B, Maloveste K, Campos N, Olson WC, Rakasz E, Watkins DI, Burton DR. 2012. Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG 2. PLoS One 7:e42209. http:// dx.doi.org/10.1371/journal.pone.0042209.
117. Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, West AP, Jr, Bjorkman PJ. 2015. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 160:433–446. http://dx.doi.org/ 10.1016/j.cell.2015.01.016.
118. Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrigue K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M, Ho DD. 2014. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343: 1151–1154. http://dx.doi.org/10.1126/science.1248707.
119. Andrews CD, Yueh YL, Spreen WR, St Bernard L, Boente-Carrera M, Rodriguez K, Gettie A, Russell-Lodrigue K, Blanchard J, Ford S, Mohri H, Cheng-Mayer C, Hong Z, Ho DD, Markowitz M. 2015. A longacting integrase inhibitor protects female macaques from repeated highdose intravaginal SHIV challenge. Sci Transl Med 7:270ra4. http://dx.doi.org/10.1126/scitranslmed.3010298.
120. Etienne L, Nerrienet E, LeBreton M, Bibila GT, Foupouapouognigni Y, Rousset D, Nana A, Djoko CF, Tamoufe U, Aghokeng AF, Mpoudi- Ngole E, Delaporte E, Peeters M, Wolfe ND, Ayouba A. 2011. Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms. Retrovirology 8:4. http://dx.doi.org/10.1186/1742-4690-8-4.
121. Humle T, Colin C, Laurans M, Raballand E. 2011. Group release of sanctuary chimpanzees (Pan troglodytes) in the Haut Niger National Park, Guinea, west Africa: ranging patterns and lessons so far. Int J Primatol 32:456–473. http://dx.doi.org/10.1007/s10764-010-9482-7.
122. Migone T-S, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135–144. http:// dx.doi.org/10.1056/NEJMoa0810603.
123. Pettitt J, Zeitlin L, do Kim H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG. 2013. Therapeutic intervention of Ebola virus infection in rhesus macaques with theMB-003monoclonal antibody cocktail. Sci Transl Med 5:199ra113. http://dx.doi.org/10.1126/scitranslmed.3006608.
124. Ghosh SK, Fultz PN, Keddie E, Saag MS, Sharp PM, Hahn BH, Shaw GM. 1993. A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Virology 194:858–864. http://dx.doi.org/10.1006/viro.1993.1331.
125. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J Virol 65: 3973–3985.
126. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819 – 822. http://dx.doi.org/10.1126/science.3646751.
127. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947–2948. http://dx.doi.org/10.1093/bioinformatics/ btm404.
128. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307–321. http://dx.doi.org/10.1093/sysbio/syq010.
129. Jones DT, Taylor WR, Thornton JM. 1992. A new approach to protein fold recognition. Nature 358:86 – 89. http://dx.doi.org/10.1038/358086a0.
130. Abascal F, Zardoya R, Posada D. 2005. ProtTest: selection of best-fit models of protein evolution. Bioinformatics 21:2104 –2105. http://dx.doi.org/10.1093/bioinformatics/bti263.
131. Ronquist F, Huelsenbeck JP. 2003. MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics 19:1572–1574. http://dx.doi.org/10.1093/bioinformatics/btg180.
132. Etienne L, Eymard-Duvernay S, Aghokeng A, Butel C, Monleau M, Peeters M. 2013. Single real-time reverse transcription-PCR assay for detection and quantification of genetically diverse HIV-1, SIVcpz, and SIVgor strains. J Clin Microbiol 51:787–798. http://dx.doi.org/10.1128/ JCM.02792-12.
133. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896 –1905. http:// dx.doi.org/10.1128/AAC.46.6.1896-1905.2002.
134. Lopker M, Easlick J, Sterrett S, Decker JM, Barbian H, Learn G, Keele BF, Robinson JE, Li H, Hahn BH, Shaw GM, Bar KJ. 2013. Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol 87:5477–5492. http://dx.doi.org/10.1128/JVI.03419-12.
135. Montefiori DC. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays, p 12.11.1–12.11. 17. In Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R (ed), Current protocols in immunology. John Wiley and Sons, New York, NY.
136. Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J. 2000. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol 74:4433–4440. http://dx.doi.org/10.1128/JVI.74.9.4433-4440.2000.
137. Decker JM, Zammit KP, Easlick JL, Santiago ML, Bonenberger D, Hahn BH, Kutsch O, Bibollet-Ruche F. 2009. Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4_ lymphocytes. Virology 394:109 –118. http://dx.doi.org/10.1016/j.virol.2009.08.027.